This review summarizes the potential for polypill therapies for stroke prevention. While a number of studies applying different approaches regarding polypill have been performed, none of them has had a focus on stroke as the main outcome. A combination pill containing drugs such as statins, diuretics, and other antihypertensives is currently available in various formats. Estimates focusing mostly on primary prevention show that using such a combination drug a reduction in the 5-year stroke incidence by 50% can be achieved -especially in low-and middle-income countries with a high prevalence of risk factors even among people at young ages. A combination of a large supporting populationwide program with a registry-based quality control is the most likely perspective and can be achieved within a reasonable time frame and potentially have significant influence in young stroke populations.
Introduction
The noncommunicable diseases (NCDs) cancer, diabetes, cardiovascular disease (CVD) (including stroke), and chronic respiratory disease account for more than 60% of all deaths globally, and it is estimated that they will be responsible for 7 in 10 deaths worldwide by 2030. 1 The cumulative estimated national income losses attributable to chronic diseases from 2005 to 2015 could exceed $1 trillion in just three countries: China, Russia, and India. 1 Therefore, the United Nations (UN) recognized NCDs as a major challenge for the 21st century and endorsed a political declaration on NCDs in 2011. 2 To realize these commitments, the World Health Assembly developed the World Health Organisation (WHO) Global Action Plan for the Prevention and Control of NCDs 2013-2020 in 2013.
3 A large part of the NCD burden is preventable, and the global NCD action plan targets behavioral risk factors (tobacco use, unhealthy diet, physical inactivity harmful use of alcohol, salt intake) as well as biological risk factors (hypertension, obesity, diabetes). At least 50% of eligible people should receive drug therapy and counseling to prevent heart attack and stroke.
Stroke is an integral part of both the 2011 UN political declaration and the post-2015 development agenda, which includes 17 sustainable development goals. 4 According to the global burden of disease study (GBD), in 2015 the estimated incidence of acute ischemic stroke was 5.39 million and for acute hemorrhagic stroke 3.58 million; the prevalence of ischemic stroke was 24.93 million and of hemorrhagic stroke 18.67 million; 2.98 million deaths were caused by ischemic stroke and 3.35 million by hemorrhagic stroke; 45.21 million disability-adjusted life-years (DALYs)
were lost due to ischemic stroke and 73.42 million due to hemorrhagic stroke. 5 Compared to the data from 1990 this corresponds to an increase of 43% in incidence, 59% in prevalence, 37% in mortality, and 22% in DALYs for all types of strokes combined. 5 As much as 90% of population attributable risk of stroke, and 91% of the stroke burden (as measured in DALYs) can be attributed to potentially modifiable risk factors. 6, 7 These factors include a cluster of metabolic factors (hypertension, obesity, high fasting plasma glucose or diabetes mellitus, high total cholesterol or high apolipoprotein B/A1 ratio, impaired kidney function, cardiac causes), behavioral factors (smoking, heavy alcohol consumption, physical inactivity, unhealthy diet, psychosocial factors), and environmental factors (air pollution and lead exposure). Risk factors often occur together and each additional risk factor multiplies stroke risk implying an advantage for a multifactorial risk factor modification approach. 8, 9 The 'Polypill'
A fixed-dose combination polypill combining several medications, which are used in clinical practice for CVD risk reduction (e.g., blood pressure (BP) and lipid lowering medications, aspirin) in conjunction with lifestyle modification, may be the optimal therapy for stroke prevention to achieve NCD goals. Polypills may close gaps in prevention and therapy, improve adherence, and simplify drug regimes. The concept of a polypill for the prevention of CVD was already proposed for primary prevention as a population treatment strategy by Wald and Law in 2003 . 10 Since then a number of polypills have been developed for the prevention of CVD, however their use is not widespread. 11 Major barriers are a low level of pharmaceutical investment, little patient advocacy, scepticism of clinicians, and hemorrhagic side effects from aspirin. 11, 12 The current WHO model list of essential medicines 2017 recognizes for cardiovascular medicines ''the potential value of fixed-dose combinations of currently listed essential medicines, with regulatory approval and demonstrated bioavailability for the management of chronic NCDs.'' 13 Estimates of the initial model of Wald and Law suggest that a polypill strategy could reduce incidence of heart attack by 88% and stroke by 80% if used by everyone aged 55 and older.
10 A more recent model using US national data suggests that with optimal prevention (intake of aspirin for high-risk individuals, control of prediabetes, weight reduction in obese individuals, BP reduction, reduction of low-density lipoprotein (LDL)-cholesterol in patients with coronary artery disease) two out of three myocardial infarctions and one out of three strokes could be prevented. 14 Following Geoffrey Rose's theorem of prevention, 15 primary prevention for stroke should use a population-wide approach and target persons with moderate to low risk to shift the risk of the global population toward lower risk. In a real-life situation, a 50% risk reduction seems more realistic than those suggested by theoretical models due to trade-offs by uncertain socioeconomic factors, low adherence, dilution of effects, and competitive morbidity.
An international scientific workshop involving stroke prevention research specialists took place in May 2017 to review the potential of a polypill as an adjunct to lifestyle modification to reduce stroke incidence by at least 50% in all major regions of the world (''Cut Stroke in Half''). The cornerstones of a population-based approach, as well as the principles for a controlled study were discussed.
Published studies for (primary) stroke prevention A systematic review was performed for randomized controlled trials (RCTs) testing the effect of a fixeddose combination (polypill) compared to usual care, placebo, or an active drug comparator for primary or secondary stroke prevention. The definition of the intervention was based on a previous definition used in a Cochrane Review, investigating the effect of a polypill for the prevention of CVD 16 : polypill was defined as a combination of several active components in a single pill with the aim to minimise stroke risk and reduce fatal and nonfatal stroke events. The polypill should include at least one statin and one antihypertensive agent. The search was performed for RCTs published in the databases Pubmed and CENTRAL (Cochrane library) before 1 May 2017. The search terms used were ''stroke,'' ''cardiovascular,'' ''fixed-dose combination,'' and ''polypill.' ' We identified 170 RCTs and clinical trials in Pubmed and 251 clinical trials in CENTRAL. None of these trials used stroke as primary outcome. However, in four RCTs stroke was included in the outcome ''major cardiovascular event'' (Table 1 17, 18, 19, 20 ). These trials were described in detail in a recent review on the use of polypills for the prevention of CVD. 11, 16 Three of these trials were secondary prevention trials for CVD and included 11-16% of stroke patients. The fourth trial was a primary prevention trial including healthy persons older than 50 years. The follow-up period of these four trials varied between 12 and 23 months with changes in LDLcholesterol, BP levels, and adherence as primary outcomes. Overall, these four RCTs included 3615 individuals and reported 28 stroke events, 17 (0.9%) in the polypill group, and 11 (0.6%) in the usual care group. The low number of events does not allow for a International Journal of Stroke, 13(6) conclusion on the effect of a cardiovascular polypill for stroke prevention. Published trials were designed to test the efficacy of a cardiovascular polypill on adherence and the targeted risk factors; BP and lipids, with follow-up periods shorter than 24 months, and thus had a low number of stroke events. Similarly, the Cochrane Review investigating the effect of polypills for the prevention of atherosclerotic cardiovascular events reports an uncertain effect on all-cause mortality, heart attacks, and stroke due to the low number of events. The meta-analysis does however show moderate to low level evidence for an effect of polypills for modest BP and cholesterol lowering and improvement of adherence. 16 Overall, 2055 adverse events were reported in 11 trials (6906 participants): 32% in the polypill arm, compared to 27% from the control arm (RR: 1.16; 95% CI: 1.09 to 1.25) . Bleeding was only reported in two studies 19, 21 ; overall only nine events were reported, eight (2%) in the polypill group versus one (0.2%) in the control group (RR: 5.68; 95% CI: 1.01 to 32.03). 16 Furthermore, we searched the International Clinical Trials Registry Platform (ICTRP), the Australian New Zealand Clinical Trials Registry (ANZCTR), ClinicalTrials.gov, ISRCTN.org, and the EU Clinical Trials Register (EU-CTR) for ongoing RCTs using polypill as intervention and stroke as outcome. No ongoing trial using stroke as primary outcome was identified. However, PROPS, secondary stroke prevention study and SECURE a secondary prevention study for myocardial infarction included stroke as a secondary outcome (Table 2) . Furthermore, three ongoing long-term studies included stroke in the outcome ''major cardiovascular events'' after 5-6 years (Table 2) .
Thus, no published or ongoing primary or secondary prevention trial has included stroke as a primary outcome. The benefits of a polypill for primary stroke prevention can only be projected from the reduction in risk factors found in these trials.
Comparative efficacy of single components
The polypill trials published to date have been mostly a proof-of concept demonstration for the use of polypills for CVD prevention. Trials designs differ in their choice of comparator groups, components and dosage of components of the polypill, and the length of observation period. To estimate the potential benefits of polypills for primary stroke prevention throughout the treatment, the components of the polypill and the estimated effect of each component should be defined for the target population.
Four primary prevention RCTs have used the observed effects of polypills on changes in BP, blood lipids, and other intermediate parameters to estimate risk reduction for stroke and cardiovascular events (Table 3 17, 18, [21] [22] [23] ).
In the Indian Polycap Study (TIPS), the polypill reduced systolic blood pressure (sBP) by 7.4 mmHg (95% CI: 6.1 to 8.1) and diastolic blood pressure (dBP) by 5.6 mmHg (95% CI: 4.7 to 6.4) after 12 weeks when compared with groups not receiving BP lowering drugs (aspirin alone or simvastatin alone). 22 However, there was no difference between the tested polypill and groups taking three BP lowering drugs. The reduction in LDL-cholesterol was 0.70 mmol/L (95% CI: 0.62 to 0.78) in the tested polypill group, compared to groups without simvastatin. Using a similar approach to Wald and Law, the authors of TIPS estimated that the tested polypill could potentially reduce stroke by 48%. This effect is lower than the 80% of stroke risk reduction after 2 years of treatment projected by Wald and Law 10 based on data from published meta-analyses of RCTs.
In a crossover RCT, the mean sBP was reduced by 17.9 mmHg (95% CI: 15.7 to 20.1) in the polypill group compared to placebo, dBP by 9.8 mmHg (95% CI: 8.1 to 11.5) and LDL-cholesterol by 1.4 mmol/L (95% CI: 1.2 o 1.6). 23 In contrast to the original risk model of Wald and Law this polypill excluded folic acid and aspirin and thus the estimated effect in reducing stroke risk was lower and assessed with 64%. 10, 23 The PILL trial found that a polypill over 12 weeks reduced sBP by 9.9 mmHg (95% CI: 7.7 to 12.1) and LDL-cholesterol by 0.8 mmol/L (95% CI: 0.6 to 0.9) compared to placebo. 21 Based on these data the authors estimated a risk reduction for stroke of 56%.
In another randomized placebo controlled trial, a polypill reduced sBP by 4.5 mmHg, total cholesterol by 0.63, and LDL-cholesterol by 0.46 after 12 months. 17 Based on these data, the authors estimated risk reduction for stroke of 21%, which is notably lower than in the other three trials. This may be due to lower baseline levels.
Sub-analyses of The Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial showed that the benefits gained by changes in risk factors were greatest for those patients who switched from a partial or a less potent treatment to polypill. 24 Polypill reduced LDL-cholesterol depending on baseline statin groups, by 0.37, 0.22, 0.14, and 0.07 mmol/L for patients taking no statin, less potent, equipotent, and more potent statin at baseline, respectively. Similarly, the reductions in mean sBP were 5.4, 6.2, 3.3, and 1.8 mmHg among patients taking 0, 1, 2, or 3 BP-lowering agents at baseline. The overall estimated reduction in CVD risk was 12.6% higher in the polypill group, and ranged from 1.4% for patients taking all medication at baseline (i.e., aspirin, a more potent International Journal of Stroke, 13(6) statin, and more than 3 BP lowering agents) to 21.4% in patients not taking aspirin at baseline. Overall, the Cochrane review investigating the effect of fixed-dose combination therapy for the prevention of atherosclerotic CVD found a mean difference between a polypill intervention and the control group for sBP of À6.34 mmHg (95% CI: À9.03 to À3.64) using data of 13 trials. Including only the eight primary prevention trials for CVDs, the effect was higher: À8.67 mmHg (95% CI: À12.41 to À4.94). The mean between group differences for total cholesterol were À0.61 mmol/l (95% CI: À0.88 to À0.35) for 11 trials, and À0.92 mmol/l (95% CI: À1.18 to À0.65) for the seven primary prevention trials. The mean between group differences for LDL cholesterol were À0.70 mmol/l (95% CI: À0.98 to À0.41) for 12 trials. These effects were comparable to the effects found in the TIPS and the PILL trial.
In addition to the effect of a combined drug therapy, lifestyle interventions have the potential to reduce stroke and CVD risk. Robinson and Maheshwari 25 suggested a poly-portfolio strategy for secondary prevention for coronary heart disease and stroke including high-dose statin, low to standard doses of antihypertensive therapy, aspirin, omega-3 fish oil, moderate physical activity, and healthy diet. They estimated that patients with coronary heart disease could reduce stroke events over 5 years by 83% when using a combined drug therapy. They estimated a relative reduction of stroke events of 38% for LDL cholesterol lowering, 63-66% for BP lowering, 19% for platelet function inhibition, and 32% for angiotensin-converting enzyme inhibitors (ACEI). No data were available to assess the combined effect of drug and lifestyle treatment on stroke risk. However, the estimated risk for further coronary heart events was 84% with a combined drug therapy and 92% with additional lifestyle therapy. 25 Persons with diabetes type 2 or prediabetes have an increased risk of stroke and coronary heart disease. This population may profit from a polypill intervention, and a primary prevention trial might enrich the number of events by using a diabetes risk assessment instrument at baseline such as the FINDRISK. 26 
Lifestyle guidelines/interventions and biomarkers
Healthy lifestyle factors such as not smoking, a body mass index <25 kg/m 2 , moderate physical activity, modest alcohol consumption, and a healthy diet add up and can lower the risk of stroke. 9 Thus, unhealthy behaviors should be targeted together, and in combination with a polypill drug intervention.
Recently the PREDIMED (Prevencio´n con Dieta Mediterra´nea) trial, a large RCT including 7447 participants who were free of CVD but at high cardiovascular risk, was the first to show that a Mediterranean diet compared to a control diet can prevent cardiovascular events and strokes after a median follow-up 4.8 years (hazard ratio for stroke: 0.61; 95% CI: 0.44 to 0.86). 27 In secondary prevention, the Lyon Diet Heart Study, an RCT with 423 patients after first myocardial infarction, has shown that the Mediterranean diet compared to a prudent Westerntype diet can reduce the occurrence of major cardiovascular events after 4 years. 28 While the evidence for the positive effect of physical exercise for stroke prevention is encouraging it comes mainly from observational studies. 29 A multicenter RCT testing instructions for a physical training program in 314 patients with ischemic stroke did not find positive effects on cardiovascular outcome events including stroke. 30 However, several small RCTs in stroke survivors showed that physical exercise can lead to beneficial reductions of BP or lipid values compared to standard care. [31] [32] [33] A number of primary and secondary prevention RCTs have tested a multifactorial approach targeting several vascular risk factors simultaneously: The Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction (GOSPEL) Study including 3241 patients with recent myocardial infarction found no significant effect of a 3-year multifactorial educational and behavioral program compared to usual care on the primary endpoint, a combination of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for angina pectoris, heart failure, or urgent revascularization procedure. However, groups did differ significantly in a secondary endpoint combing cardiovascular mortality plus nonfatal myocardial infarction and stroke. 34 A secondary diabetes prevention trial, the Steno-2 trial, showed that an intensified intervention over 7.8 years with behavior modification and pharmacologic therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and microalbuminuria, along with aspirin, reduced the risk of cardiovascular events among 160 patients with type 2 diabetes and microalbuminuria by about 50% when compared to usual care. 35 This benefit persisted at a follow-up after 13.3 years. 36 In contrast, the Look AHEAD (Action for Health in Diabetes) study in 145 overweight or obese patients with type 2 diabetes found no significant difference in cardiovascular morbidity and mortality between a group with intensive lifestyle intervention and a group receiving diabetes support and education after a median follow-up time of 9.6 years. 37 However, the intensive lifestyle intervention had greater reductions in weight, glycated hemoglobin, sBP and greater improvements in fitness. The between-group differences International Journal of Stroke, 13 (6) in cardiovascular risk factors were largest after the first year and diminished over time. Similarly, a third RCT in 1173 elderly type 2 diabetes patients found no effect of an intensive multifactorial intervention on cardiovascular outcomes compared to usual care after 6 years of follow-up. 38 Except for HbA1c at year 1, no group differences were found for vascular risk factors (BP, lipids, BMI) during the 6 years. This suggests that lifestyle modification have to be strong enough to create group differences and to be maintained over longer periods to prevent cardiovascular events.
A systematic review including 20 RCTs (6373 strokes) analyzed the effectiveness of multimodal behavioral interventions for secondary stroke prevention. 39 Intervention types, duration, and intensity were highly variable. Significant benefits of a multifactorial intervention were found on BP (mean change in sBP: À4.21 mmHg, 95% CI: À6.24 to À2.18; in dBP: 2.03 mmHg, 95% CI: À3.19 to À0.87) and in waist circumference (mean change: À6.69 cm, À11.44 to À1.93), but not for HDL, LDL, total cholesterol, fasting blood glucose, BMI, weight or waist to hip ratio, smoking cessation, or fruit and vegetable consumption. No effect was found for death or recurrent stroke, however, there was a significant reduction of cardiac events (OR: 0.38, 95% CI: 0.16 to 0.88). The Austrian Polyintervention Study to Prevent Cognitive Decline after Ischemic Stroke (ASPIS) was an RCT of 202 stroke patients, designed to test the efficacy of a 2-year multifactorial intervention program with focus on improvement in lifestyle and vascular risk factors compared to standard care for the prevention of cognitive decline after stroke. It showed improvement in the lifestyle profile of stroke patients as measured by a lifestyle summary score after 2 years. 40 Other than BP and blood lipids, biomarkers or surrogate outcomes that have been used to test the efficacy of lifestyle interventions include endothelial function, arterial stiffness, carotid intima-media thickness (CIMT), and insulin resistance. The Risk Intervention Study (RIS) study, an RCT in 508 hypertensive patients at high cardiovascular risk, showed that a comprehensive risk factor modification program can lower the rate of cardiovascular events during 6 years of follow-up compared with usual care. A carotid ultrasound substudy of RIS in 60 patients suggests that the benefit gained by the interventions is confined to patients with echolucent plaques at baseline. 41 A retrospective cohort study in 324 patients receiving lipid-lowering medications and lifestyle modification at a community prevention clinic with a mean observation period of 3 years, showed a decline in max CIMT of 30% after 1 year, of 53% after 2 years with a stable trend afterwards, and a change in plaque composition, including a decrease in lipid-rich plaques of 78% by the second years. These changes corresponded to significant improvements in lipid parameters and sBP during the first year of treatment, with stable trends afterwards, suggesting that CIMT may be a useful biomarker for cardiovascular risk. 42 In summary, life style interventions are effective in improving risk factor controls in primary and secondary preventive settings, especially for BP, and in changing lifestyle toward a healthier profile. In secondary prevention, cardio-and cerebrovascular outcomes can be reduced by multifactorial/lifestyle oriented interventions-provided that relevant differences in risk behavior between treatment and control group can be achieved and maintained. CIMT is an adequate surrogate outcome parameter to monitor atherosclerotic CVD progression in trials with lifestyle interventions.
Experiences in a developing country
India ranks second to China in terms of population size. For example, the city of Kolkata has 14.6 million inhabitants with a catchment area for medical care of 580 million when areas such as Bangladesh, Nepal, Myanmar, and Bhutan are included. Stroke is one of the leading causes of death and disability in India. The estimated adjusted annual prevalence of stroke ranges from 262 to 545/100,000 people and the age standardized annual incidence rates for first ever strokes ranges from 135 to 152/100,000 person-years. 43 Thus about 1.7 million strokes occur every year in India. Case-fatality was found to be higher than in developed countries. A prospective community-based study in Kolkata found a 30-day case fatality of 41% and a rate of stroke-related DALYs of 796/100,000 personyears. 44, 45 This may partly be due to the larger proportion (32%) of hemorrhagic strokes. 44 Stroke in developing countries often occurs at younger age than in developed countries. Hospitalbased studies in India found the proportion of young strokes ( 40 years) to range between 15% and 30%. 46 However, a well-designed population based study in Kolkata found a much lower proportion which suggests some bias due to hospital admission policy in hospital-based studies. 44 Hypertension is highly prevalent in India. According to the GBD study, the number of deaths related to sBP increased in India from 1990 to 2015 from 812,000 to 1,638,000 for sBP 110-115 mmHg and from 449,000 to 1,012,000 for sBP ! 140 mmHG. 47 In another GBD study, an increased sBP in India accounted for 59.4% stroke-related DALYs. 7 A survey in an urban community in eastern India found a prevalence of 48% for hypertension (sBP ! 140 mmHG) and 36% for prehypertension (sBP: 120-139 mmHg). 48 The prevalence of prehypertension was high among younger
International Journal of Stroke, 13 (6) subjects-particularly students and laborers. A community study of south India showed that only 37% of patients with hypertension were previously aware of its existence, half of them took medication regularly, and again half of them were well controlled. 49 Thus, the awareness, treatment, and control for hypertension seem to be inadequate. The Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study, a large cross-sectional survey in 14,059 Indians older than 20 years, found an overall age-standardized prevalence of hypertension of 26%; which was selfreported in only 5% and newly detected in 21% of the cases. 50 Additionally, this study reports a high prevalence of dyslipidaemia in India: 30% had hypertriglyceridemia, 72% had low high-density lipoprotein (HDL) cholesterol levels, 12% had high LDL cholesterol levels, and 79% had abnormalities in one of the lipid parameters. 51 Elevated BP is already prevalent at a young age, as shown by a cross-sectional study in eastern India which found that among 2913 school going adolescents 11% had prehypertension and 5% hypertension. 52 Ischemic stroke in young Indians (15-45 years) was associated with a high prevalence of smoking, high sBP, high fasting blood glucose, low HDL cholesterol, and the presence of !3 metabolic syndrome components when compared with community controls. 53 In a tertiary hospital database in North India, the most common risk factors for stroke in the age group 18-45 (n ¼ 440, 17%) were hypertension (34%), dyslipidaemia (27%), and prior stroke. 54 In another North Indian hospital database, hypertension was identified as the etiology for intracerebral hemorrhage in 79% of 404 young patients (16-50 years). 55 In developing countries, a large proportion of patients do not receive appropriate medication. According to the WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE), a cross-sectional survey in a sample of 10,000 coronary heart disease and cerebrovascular disease patients in low-and middle-income countries, proportions of stroke patients who had received medications were 70.6% for aspirin, 22.8% for beta-blockers, 37.8% for ACEI, and 14.1% for statins. 56 As in other developing countries, the implementation of treatments for secondary prevention in India is suboptimal. A large-scale survey investigating secondary prevention in a rural area of India identified cerebrovascular disease as responsible of all-cause mortality in 15% of 1146 verbal autopsies and coronary heart disease in 16% of cases. Despite the high burden attributable to CVD, only 14% of 4535 persons with non-fatal CVD were taking aspirin, 41% took a BP-lowering medication, and only 5% reported using a cholesterol-lowering medication. 57 Similarly, in the Coronary Artery Disease in the Young (CADY) registry, a multicenter, prospective, observational study across India, including 997 patients with acute coronary syndrome or stable ischemic heart disease, antiplatelet medication was used by 85%, beta-blockers by 38%, statins by 63%, and ACEI/angiotensin-II receptor blockers (ARBs) by 41% patients at hospital discharge despite of a family history of premature coronary artery disease in 50% of patients. 58 Similarly, analyses based on data of 14,333 stroke patients included in the China National Stroke Prevention Project showed that the proportion of patients who received all required combinations of separate pills was only 7% at the time of the survey. 59 The study estimated that 54% of patients would be eligible for a secondary prevention polypill strategy in China, that is, for a combination of antihypertensive, statin, and antiplatelet medications.
Cardiovascular secondary prevention medications are often not available or affordable in low-and middle-income countries. The Prospective Urban Rural Epidemiology (PURE) study analyzing data from 596 communities in 18 countries found that availability for four CVD medicines (aspirin, beta blockers, ACEI, and statins) decreased from 95% of urban and 90% of rural communities in high-income countries to 25% of urban and 3% of rural communities in lowincome countries, whereas they were potentially unaffordable (combined cost more than 20% of household capacity-to-pay) for only 0Á14% of households in high-income countries compared to 60% of low-income countries. 60 In India, given its large, generic pharmaceutical industry, the availability was higher with 89% of urban and 81% of rural communities, and the potential unaffordability for 59% of households.
A polypill strategy might be optimal for stroke prevention in a developing region such as India with a large, relatively young population at high cardiovascular risk, low awareness of risk factors, and with low compliance in primary and secondary prevention treatment. A publicly financed mass-strategy with a single polypill available at low cost may increase compliance for primary prevention and might be superior to an individual approach with several medications. In developing countries with stroke occurring at younger age, polypill interventions containing just BP and lipid-lowering components could start at younger age (e.g., 40 years). Inclusion of aspirin in the polypill in these settings should be avoided because of its known hemorrhagic side effects and the already high risk of hemorrhagic strokes in developing countries. Smartphone apps can be used as cheap recruitment and motivational tools in a large population that does not necessarily have access to medical doctors.
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Cornerstones for stroke prevention trials
Designing a trial to test the efficacy of a polypill intervention to avoid or delay stroke includes a number of considerations on the choices of the study population, the intervention, components of the polypill, and the endpoints.
First, a choice has to be made whether the approach should be for primary or secondary prevention, that is, whether the participants should be stroke-free at baseline. A population-wide strategy in a low-to moderaterisk population with the aim to shift the distribution of risk factors toward lower risk, advocates for a mainly primary prevention trial. The selection criteria for the target population have to balance between efficacy and generalizability of the trial, that is, between a low-risk population where a low number of events is to be expected in the near future, and thus a large sample size and a long follow-up period will be required to measure the effect of the intervention on stroke, and a high-risk population where the number of expected preventable events is higher but which represent only a small part of the total population. The definition for population risk may be based on a single risk factor (e.g., hypertension, prehypertension (sBP: 120-139 mmHG), hypercholesterolemia, prediabetes, CIMT, or older age), or on a global risk score which may be assessed using simple tools (e.g., Framingham stroke risk algorithm, 61 Qstroke algorithm, 62 Stroke Riskometer app 63 ). For a greater generalizability, the population for a primary stroke prevention trial should maximize heterogeneity in sex and ethnicity. It has been suggested that prevention for CVD and stroke should start at the age of 55 years. 10 However, in developing countries populations are younger and stroke risk is shifted toward younger population, thus primary prevention may start at a younger age (e.g., 40) in these populations. Furthermore, behavioral changes have the highest benefit if achieved early in life. Selection criteria have to assure to exclude persons for whom a component of the polypill is likely to be harmful (e.g., allergy, severe renal/liver failure, high risk of bleeding), persons who are unlikely to adhere to the intervention because of drug, psychiatric, or cognitive problems, because of severe comorbidities with a life-expectancy lower than 5 years, or language and communication problems.
An intervention using a single pill such as the polypill has the advantage of simplicity, the possibility for blinding, and lower contamination issues compared to a multifactorial behavioral intervention. Nonpharmacological (lifestyle  or  education) interventions on the other hand have the advantage of low safety concerns and a better generalizability due to broader selection criteria. Nevertheless, lifestyle interventions have large potential for reducing stroke risk and should thus be included in a population wide primary stroke prevention strategy. Polypills considered for the prevention of CVDs generally include at least one anti-hypertensive drug, a statin and sometimes (e.g., for high CVD risk individuals) aspirin. 64 The dosage of single components, the number and type of anti-hypertensives, and especially the bleeding risk associated with the use of aspirin have been discussed for the choice of an optimal composition for a polypill designed for primary stroke prevention. Four different polypill types may be chosen depending on individual risk:
1. primary prevention, low to moderate CVD risk: statin þ ARB þ hydrochlorothiazide (HCTZ); 2. primary prevention, high CVD risk: aspirin þ statin þ ARB þ HCTZ; 3. secondary prevention of ischemic stroke: aspirin þ high dose statin þ full dose ARB/ACEI þ HCTZ; and 4. secondary prevention of hemorrhagic stroke: full dose ARB/ACEI þ HCTZþ (for patients with atherosclerosis) high dose statin.
Primary outcomes can be hard endpoints such as fatal or nonfatal strokes and TIA, or soft endpoints having a strong association with stroke occurrence such as single stroke risk factors (e.g., sBP), risk factor scores (Life's Simple 7 (LS7)), or global stroke risk scores. The advantage of choosing hard endpoints compared to soft endpoints is that they are definitive outcomes with no time-lag between the measurement of stroke risk and the incidence of stroke; however, large sample sizes and longer follow-up periods are needed-especially in young and low-risk populations. Compared to a global risk score, using single risk factors as outcomes has the advantage of being simple to measure and easy to interpret, but do not reflect a real-life situation and may be difficult to generalize. Secondary endpoints should reflect additional positive or negative (adverse events) effects of the intervention and should measure aspects relevant to the implementation of the intervention into practice.
Specific challenges for primary prevention trials in the elderly are recruitment, retention of participants, compliance with the interventions, and adherence to follow-ups. Possible solutions which should be considered during planning are to ensure easy access to study sites, home visits, flexible study hours, reimbursement for travel fees, pick-up services to the study site, a close network with community organizations, and to monitor for psychosocial problems.
Despite possible disadvantages, cluster randomization, stratification, and minimization techniques might be strategies to lower contamination, increase compliance and increase balance for prognostic factors between groups in randomized multicenter behavioral trials. In behavioral stroke prevention trials which often have a high risk of contamination, a Zelen design may be considered and information on contaminating factors should be collected and included in analyses. 65 A Zelen design randomizes patients before asking for their consent and can offer alternative treatment if they decline. This can help to avoid problems with recruitment, compliance, and bias which may occur when patients are disappointed with the allocated treatment. 65 Sensitivity analyses and Complier Average Casual Effect (CACE) analysis should be planed. 65 Other challenges for behavioral trials in primary stroke prevention are the motivation of the participants, the complexity of the interventions, the costs of the interventions including their Figure 1 . Flowchart illustrating the cornerstones for a large international study testing a polypill for stroke prevention in low-to middle-income countries. International Journal of Stroke, 13 (6) implementation-especially in resource-poor countries, and the often-lower research priority of behavioral compared to drug trials. Mobile technologies such as smartphone apps with built-in motivational components (e.g., goal setting, relative risks along with the absolute risk estimates, progress monitoring, feedbacks, etc.) may be low-cost opportunities to increase participants' motivation.
Sample size and trial duration have to be determined depending on the choice of the primary outcome variable (hard or soft endpoint, clinically meaningful difference), the sustainability of the treatment effect, the expected drop-outs, nonadherence, adverse events, contamination, and the allowable budget.
Decisive elements for a large observational study and for a controlled trial
The experts agreed that a successful large trial testing a polypill for stroke prevention should aim at primary prevention and target a large, moderate-risk population (corresponding to a 5-14% 5-year CVD risk) in low-to middle-income countries. If practicable and implementable in low resource countries, the preferred design, providing the most conclusive results would be an RCT which could be performed in a subpopulation nested within a larger observational study (Figure 1 ).
New internet-or smartphone-based technologies for recruitment, assessment of stroke risk, delivering interventions, motivation, and monitoring of patients are likely to be efficient to increase recruitment rates, adherence, and compliance. Viewing the world-wide increase in the use of smartphones, the Stroke Riskometer app might be a good example for such a tool. 63 A smartphone app-based strategy has the potential to reach a large population including persons that have no regular contact with medical doctors. The Stroke Riskometer app has been validated and endorsed by major international and national stroke organizations. It informs people of their absolute risk and also their relative risk of having a stroke within the next 5-10 years, which might motivate them to reduce their risk of stroke.
Health community workers should be involved in recruitment, monitoring, outcome assessment, and motivation of patients. Community workers can help to tailor interventions to the cultural, social, economic, and environmental context, and can help to overcome barriers to seeking and delivering health care, and facilitate behavioral modification and drug compliance. 66 
Summary and conclusion
During a recent workshop, stroke specialists discussed the potential for a polypill, a multi-compartmentalized tablet containing a combination of antihypertensive and lipid lowering drugs in small dosage, with a focus on primary stroke prevention. Previous studies have shown efficacy for adherence and risk factor decrease in CVD patients, mostly in secondary prevention, but so far not for hard CVD endpoints. However, no RCT has tested a polypill for stroke prevention. Estimates for stroke risk reduction calculations based on the expected reduction in risk factors and the expected better compliance suggest that a polypill in adjunction to lifestyle interventions has the potential to reduce the stroke burden in accordance with the NCD goals (''Cut Stroke in Half''). A project for stroke prevention should use a population-wide approach in a high-risk area in the world and target persons with an intermediate risk of suffering stroke. Numerous experiences to date show that stroke incidence can be strongly influenced by uniting life style health interventions and a polypill strategy in a moderate risk population. Within an observation time of 5 years or more a 50% reduction of stroke incidence can be achieved. A combination of a large supporting population-wide program with a registry-based quality control is the most likely perspective and can be achieved within a reasonable time frame.
